Hepatocellular Carcinoma Non-resectable
2 competing products in clinical development for Hepatocellular Carcinoma Non-resectable.
Pipeline by Phase
Phase 1/21
Phase 21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| mFOLFOX7 combined with Camrelizumab and apatinib | Sun Pharmaceutical | Phase 2 | Recruiting | 42 |
| Lenvatinib | Eisai | Phase 1/2 | Active | 36 |